Moody Aldrich Partners LLC boosted its stake in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 17.3% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 47,190 shares of the biotechnology company’s stock after buying an additional 6,965 shares during the period. Moody Aldrich Partners LLC’s holdings in Momenta Pharmaceuticals were worth $1,570,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in MNTA. Victory Capital Management Inc. boosted its stake in Momenta Pharmaceuticals by 31.2% in the 4th quarter. Victory Capital Management Inc. now owns 15,148 shares of the biotechnology company’s stock valued at $299,000 after buying an additional 3,606 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Momenta Pharmaceuticals by 45.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 636,481 shares of the biotechnology company’s stock valued at $12,558,000 after buying an additional 197,524 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Momenta Pharmaceuticals by 6.8% in the 4th quarter. Bank of New York Mellon Corp now owns 1,206,211 shares of the biotechnology company’s stock valued at $23,798,000 after buying an additional 77,313 shares in the last quarter. AQR Capital Management LLC acquired a new position in Momenta Pharmaceuticals in the fourth quarter worth $334,000. Finally, Man Group plc grew its holdings in shares of Momenta Pharmaceuticals by 1.9% during the fourth quarter. Man Group plc now owns 148,417 shares of the biotechnology company’s stock worth $2,928,000 after purchasing an additional 2,708 shares during the last quarter. 96.92% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:MNTA traded down $0.83 during trading on Friday, hitting $29.49. 1,102,026 shares of the company’s stock were exchanged, compared to its average volume of 857,756. Momenta Pharmaceuticals, Inc. has a 1-year low of $10.71 and a 1-year high of $39.88. The firm has a 50-day moving average price of $33.92 and a two-hundred day moving average price of $30.78. The firm has a market cap of $3.47 billion, a P/E ratio of -10.53 and a beta of 1.51.
Several research analysts recently issued reports on the stock. ValuEngine downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. JPMorgan Chase & Co. raised their price objective on shares of Momenta Pharmaceuticals from $37.00 to $42.00 and gave the company an “overweight” rating in a research report on Tuesday, June 16th. BidaskClub cut shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, July 24th. Cantor Fitzgerald raised their price objective on shares of Momenta Pharmaceuticals from $30.00 to $38.00 and gave the company a “neutral” rating in a research report on Tuesday, June 16th. They noted that the move was a valuation call. Finally, Wells Fargo & Co raised their price objective on shares of Momenta Pharmaceuticals from $40.00 to $48.00 and gave the company an “overweight” rating in a research report on Monday, June 15th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Momenta Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $43.44.
In other Momenta Pharmaceuticals news, CEO Craig A. Wheeler sold 2,778 shares of Momenta Pharmaceuticals stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $31.23, for a total value of $86,756.94. Following the transaction, the chief executive officer now owns 18,091 shares of the company’s stock, valued at $564,981.93. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Agnieszka Cieplinska sold 940 shares of the business’s stock in a transaction on Friday, June 12th. The stock was sold at an average price of $30.15, for a total transaction of $28,341.00. Following the completion of the sale, the chief accounting officer now directly owns 6,311 shares in the company, valued at approximately $190,276.65. The disclosure for this sale can be found here. In the last quarter, insiders have sold 215,176 shares of company stock valued at $7,091,801. 3.40% of the stock is owned by corporate insiders.
Momenta Pharmaceuticals Profile
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.
Featured Article: Nikkei 225 Index
Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.